This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surface Oncology マネジメント

マネジメント基準チェック /34

Surface Oncologyの CEO はRob Rossで、 Apr2021年に任命され、の在任期間は 2.42年です。の年間総報酬は$ 1.92Mで、 29.5%給与と70.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.14%を直接所有しており、その価値は$ 89.02K 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と4.7年です。

主要情報

Rob Ross

最高経営責任者

US$1.9m

報酬総額

CEO給与比率	29.5%
CEO在任期間	2.4yrs
CEOの所有権	0.1%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	4.7yrs

経営陣の近況

Recent updates

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Nov 07

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Aug 08

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Aug 03

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

May 25

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

May 11

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Mar 15

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 16

Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

Dec 09

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Dec 08

Surface Oncology shares rise 13% on Fast Track tag for SRF388

Nov 11

CEO報酬分析

Surface Oncology の収益と比較して、Rob Ross の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2023	n/a	n/a	-US$93m
Mar 31 2023	n/a	n/a	-US$90m
Dec 31 2022	US$2m	US$568k	-US$64m
Sep 30 2022	n/a	n/a	-US$66m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$57m
Dec 31 2021	US$5m	US$506k	-US$78m
Sep 30 2021	n/a	n/a	US$13m
Jun 30 2021	n/a	n/a	US$17m
Mar 31 2021	n/a	n/a	US$21m
Dec 31 2020	US$1m	US$435k	US$59m
Sep 30 2020	n/a	n/a	-US$24m
Jun 30 2020	n/a	n/a	-US$25m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$810k	US$400k	-US$55m
Sep 30 2019	n/a	n/a	-US$44m
Jun 30 2019	n/a	n/a	-US$44m
Mar 31 2019	n/a	n/a	-US$35m
Dec 31 2018	US$880k	US$361k	-US$7m
Sep 30 2018	n/a	n/a	-US$18m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$467k	US$329k	-US$45m

報酬と市場: Robの総報酬 ($USD 1.92M ) は、 US市場 ($USD 646.00K ) の同規模の企業の平均を上回っています。

報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Rob Ross (49 yo)

2.4yrs

在職期間

US$1,924,455

報酬

Dr. Robert W. Ross, also known as Rob, M.D., is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Independent Director at Xilio Therapeutics, Inc....

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Ross	President	2.4yrs	US$1.92m	0.14% $ 89.0k
Alison O'Neill	Chief Medical Officer	3.6yrs	US$1.06m	データなし
Jessica Fees	CFO & Treasurer	4.8yrs	データなし	0.17% $ 109.1k
Chandra Adams	Deputy General Counsel & Secretary	less than a year	データなし	0.051% $ 33.1k
Lisa McGrath	Chief People Officer	no data	データなし	データなし
Shannon Devens	Senior Vice President of Development Operations	1.8yrs	データなし	データなし

2.4yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: SURFの経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Ross	President	2.4yrs	US$1.92m	0.14% $ 89.0k
Charles Sigal	Independent Member of Scientific Advisory Board & Director	5.6yrs	US$80.57k	0.075% $ 48.6k
David Grayzel	Independent Director	9.4yrs	US$84.57k	0% $ 0
J. Goater	Director	5.6yrs	US$72.57k	0.21% $ 138.3k
Alexander Rudensky	Member of Scientific Advisory Board	4.7yrs	データなし	データなし
Armen Shanafelt	Independent Director	8.8yrs	US$89.07k	0% $ 0
Laurie Stelzer	Independent Director	5.6yrs	US$92.57k	0% $ 0
F. Hodi	Member of Scientific Advisory Board	no data	データなし	データなし
Denice Torres	Independent Chairman & Lead Independent Director	2.2yrs	US$151.82k	0% $ 0
Christopher Hunter	Member of Scientific Advisory Board	4.7yrs	データなし	データなし
Carla Rothlin	Member of Scientific Advisory Board	4.7yrs	データなし	データなし
Arlene Sharpe	Member of Scientific Advisory Board	4.7yrs	データなし	データなし

4.7yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: SURFの取締役会は経験豊富であると考えられます ( 4.7年の平均在任期間)。

This company has been acquired

Surface Oncology マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Chairman of the Board exercised options and sold US$862k worth of stock

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

Recent updates

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Consensus revenue estimates decrease by 17%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Price target decreased to US$5.25

Consensus forecasts updated

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

Consensus revenue estimates increase by 46%

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Price target decreased to US$13.00

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Consensus forecasts updated

Price target decreased to US$14.75

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Surface Oncology: Staying The Course

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$21.0m

Investor sentiment deteriorated over the past week

Surface Oncology: A Diverse, But Early Pipeline

Chairman of the Board exercised options and sold US$862k worth of stock

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$28.1m

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology EPS beats by $0.04, beats on revenue

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Analysts lower revenue estimates to US$18.8m

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

New 90-day low: US$7.53

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

CEO, President & Director notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

New 90-day high: US$10.70

Analysts update estimates

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

マネジメント基準チェック /34